<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Volegova MP</submitter><funding>NCATS NIH HHS</funding><funding>Alex&amp;apos;s Lemonade Stand Foundation for Childhood Cancer</funding><funding>NCI NIH HHS</funding><funding>National Institutes of Health</funding><funding>NIGMS NIH HHS</funding><pagination>114134</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11284644</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>43(5)</volume><pubmed_abstract>Tumor MYCN amplification is seen in high-risk neuroblastoma, yet direct targeting of this oncogenic transcription factor has been challenging. Here, we take advantage of the dependence of MYCN-amplified neuroblastoma cells on increased protein synthesis to inhibit the activity of eukaryotic translation initiation factor 4A1 (eIF4A1) using an amidino-rocaglate, CMLD012824. Consistent with the role of this RNA helicase in resolving structural barriers in 5' untranslated regions (UTRs), CMLD012824 increased eIF4A1 affinity for polypurine-rich 5' UTRs, including that of the MYCN and associated transcripts with critical roles in cell proliferation. CMLD012824-mediated clamping of eIF4A1 spanned the full lengths of mRNAs, while translational inhibition was mediated through 5' UTR binding in a ca</pubmed_abstract><journal>Cell reports</journal><pubmed_title>The MYCN 5' UTR as a therapeutic target in neuroblastoma.</pubmed_title><pmcid>PMC11284644</pmcid><funding_grant_id>R35 GM118173</funding_grant_id><funding_grant_id>R21 CA267521</funding_grant_id><funding_grant_id>U01 TR002625</funding_grant_id><pubmed_authors>Banerjee U</pubmed_authors><pubmed_authors>George RE</pubmed_authors><pubmed_authors>Sharma B</pubmed_authors><pubmed_authors>Kennedy A</pubmed_authors><pubmed_authors>Volegova MP</pubmed_authors><pubmed_authors>Porco JA</pubmed_authors><pubmed_authors>Dries R</pubmed_authors><pubmed_authors>Brown LE</pubmed_authors></additional><is_claimable>false</is_claimable><name>The MYCN 5' UTR as a therapeutic target in neuroblastoma.</name><description>Tumor MYCN amplification is seen in high-risk neuroblastoma, yet direct targeting of this oncogenic transcription factor has been challenging. Here, we take advantage of the dependence of MYCN-amplified neuroblastoma cells on increased protein synthesis to inhibit the activity of eukaryotic translation initiation factor 4A1 (eIF4A1) using an amidino-rocaglate, CMLD012824. Consistent with the role of this RNA helicase in resolving structural barriers in 5' untranslated regions (UTRs), CMLD012824 increased eIF4A1 affinity for polypurine-rich 5' UTRs, including that of the MYCN and associated transcripts with critical roles in cell proliferation. CMLD012824-mediated clamping of eIF4A1 spanned the full lengths of mRNAs, while translational inhibition was mediated through 5' UTR binding in a ca</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2026-06-02T23:35:09.754Z</modification><creation>2025-04-19T13:12:24.609Z</creation></dates><accession>S-EPMC11284644</accession><cross_references><pubmed>38662542</pubmed><doi>10.1016/j.celrep.2024.114134</doi></cross_references></HashMap>